Stocks · 4 Min Read
From Bulk Chemistry to High-Margin Brands: Analyzing Citi Pharma’s Acquisition of Pakheim
How a 100% buyout allows Citi Pharma to skip years of regulatory queues, double-dip on API margins, and pivot toward high-value retail healthcare.
For years, Pakistan’s pharmaceutical industry has been split into two distinct tracks: the raw-material producers who supply Active Pharmaceutical Ingredients (APIs)—the underlying chemicals—and the brand owners who sell finished tablets, s
Sign In To ReadNot investment advice. Advisors on Portfolio360 share their own views.